Literature DB >> 35237371

Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose.

Muhammad Akbar Baig1, Joshua Nogar1.   

Abstract

Entities:  

Year:  2022        PMID： 35237371      PMCID： PMC8861345          DOI： 10.5847/wjem.j.1920-8642.2022.050

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN： 1920-8642


× No keyword cloud information.
  8 in total

1.  Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.

Authors:  Giovanni Antonio Silverii; Matteo Monami; Edoardo Mannucci
Journal:  Diabetes Obes Metab       Date:  2020-12-23       Impact factor: 6.577

2.  Ertugliflozin (Steglatro): A New Option for SGLT2 Inhibition.

Authors:  Nikolas Kovacich; Benjamin Chavez
Journal:  P T       Date:  2018-12

3.  Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers.

Authors:  Scott E Schaeffer; Carol DesLauriers; Henry A Spiller; Alfred Aleguas; Salvador Baeza; Mark L Ryan
Journal:  Clin Toxicol (Phila)       Date:  2017-08-16       Impact factor: 4.467

Review 4.  SGLT2 inhibitors: are they safe?

Authors:  Sebastian Filippas-Ntekouan; Theodosios D Filippatos; Moses S Elisaf
Journal:  Postgrad Med       Date:  2017-10-27       Impact factor: 3.840

Review 5.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Authors:  Sunil Nair; John P H Wilding
Journal:  J Clin Endocrinol Metab       Date:  2009-11-05       Impact factor: 5.958

6.  Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

Authors:  Li-Min Zhao; Miao Zhang; Ze-Lin Zhan; Mei Qiu
Journal:  Front Cardiovasc Med       Date:  2021-05-05

Review 7.  Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.

Authors:  James W Reed
Journal:  Vasc Health Risk Manag       Date:  2016-10-27

Review 8.  Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.

Authors:  Vivian T Thieu; Beth D Mitchell; Oralee J Varnado; Brian M Frier
Journal:  Diabetes Obes Metab       Date:  2020-01-03       Impact factor: 6.577
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.